Onbrez Breezhaler Inhalation (Dry Powder)
Indacaterol
150mcg
Novartis Pharma AG
| Pack size | 30's (10's Blister x 3) + Onbrez Breezhaler |
|---|---|
| Dispensing mode | POM |
| Source | SWITZERLAND |
| Agent | ALPHAMED DRUG STORE |
| Retail Price | 211.50 AED |
Indications
Onbrez Breezhaler Inhalation (Dry Powder) is used for:
Indacaterol Maleate is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with, chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Adult Dose
Inhalation
Maintenance therapy in chronic obstructive pulmonary disease
Adult: As inhal cap: Inhale 75-150 mcg once daily using inhaler.
Max: 300 mcg once daily.
Hepatic impairment
No dose adjustment is required for patients with mild and moderate hepatic impairment.
There are no data available for use of Onbrez Breezhaler in patients with severe hepatic impairment.
Child Dose
Safety and efficacy not established
Renal Dose
Renal impairment
No dose adjustment is required for patients with renal impairment.
Administration
Contra Indications
All LABA are contraindicated in patients with asthma without use of a long-term asthma control medication. Indacaterol is not indicated for the treatment of asthma. Indacaterol is contraindicated in patients with a history of hypersensitivity to indacaterol or to any of the ingredients.
Precautions
Not intended for treatment of asthma and acute deterioration of COPD. Patient w/ acutely deteriorating COPD, thyrotoxicosis, seizure disorders, DM, hypokalaemia, CV disorders esp coronary insufficiency, cardiac arrhythmias or HTN. Pregnancy and lactation.
Lactation: Unknown whether distributed in human breast milk; use caution
Pregnancy-Lactation
Pregnancy Category: C
Beta-agonists are known to inhibit uterine contractility
Lactation: Unknown whether distributed in human breast milk; use caution
Interactions
Potentiated adverse effects w/ other sympathomimetic agents; possible hypokalaemic effect w/ methylxanthine derivatives, steroids or non-K-sparing diuretics. Other long-acting beta2-adrenergic agonists or medicinal products containing long-acting beta2-adrenergic agonists. Inhibition of the key contributors of indacaterol clearance, CYP3A4 and P-gp.
Adverse Effects
Side effects of Indacaterol :
>10%
Post-inhalation cough (24% compared with 7% on placebo)
1-10%
Cough (6.5%), Nasopharyngitis (5.3%), Headache (5.1%), Nausea (2.4%), Oropharyngeal pain (2.2%)
Potentially Fatal: Asthma-related deaths.
Mechanism of Action
Indacaterol is a long acting β2-adrenergic agonist. It relaxes the bronchial smooth muscle by selective action on β2-receptor which acts locally in the lungs and w/ little effect on heart rate.
Note
Onbrez Breezhaler 150mcg Inhalation (Dry Powder) manufactured by Novartis Pharma AG. Its generic name is Indacaterol. Onbrez Breezhaler is availble in United Arab Emirates.
Farmaco UAE drug index information on Onbrez Breezhaler Inhalation (Dry Powder) is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.